Abstract.
Objective: To investigate the influence of concomitant administration of roxithromycin on the plasma pharmacokinetics of lovastatin. Methods: In an open, randomized, crossover study, 12 healthy volunteers received 80 mg lovastatin orally either alone or concomitantly with 300 mg roxithromycin after 5-day pretreatment with roxithromycin 300 mg daily. Plasma concentrations of lovastatin (lactone and acid) were determined using high-performance liquid chromatography, and the pharmacokinetic parameters were estimated. Results: The mean (±SD) pharmacokinetic parameters of lovastatin lactone with and without roxithromycin were maximum concentration (Cmax) 8.49±6.80/16.3±9.4 ng ml–1, time to Cmax (tmax) 1.8±0.4/1.7±0.6 h, terminal plasma half-life (t 1/2) 4.3±2.0/3.7±2.5 h, area under the plasma concentration–time curve from zero to infinity (AUC0– ∞) 53±60/85±67 ng ml–1 h. The respective parameters of lovastatin acid were Cmax 24.6±13.4/17.8±11.0 ng ml–1, tmax 3.7±1.1/4.1±0.7 h, t 1/2 3.2±2.5/4.3±2.8 h, AUC0– ∞ 149±123/105±58 ng ml–1 h. Mean bioavailability of lovastatin lactone was lower and that of lovastatin acid was higher with concomitant treatment. However, the differences were significant only with respect to lovastatin lactone (AUC and Cmax) and Cmax of lovastatin acid. Conclusion: Roxithromycin does not influence the pharmacokinetics of lovastatin in such a way that dosage adjustment of lovastatin seems to be necessary during co-administration.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Author information
Authors and Affiliations
Additional information
Accepted in revised form: 25 August 2001
Electronic Publication
Rights and permissions
About this article
Cite this article
Bucher, M., Mair, G. & Kees, F. Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. Eur J Clin Pharmacol 57, 787–791 (2002). https://doi.org/10.1007/s00228-001-0385-6
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-001-0385-6